Everads Therapy
Delivery System for Injectable Therapies into the Eye
Company Overview
Snapshot
Founded in January 2017 by Dr. Ifat Sher, Dr. Ygal Rotenstreich, and David Daily, Everads Therapy is an early-stage life sciences company with 1–10 employees. The company has raised $1 million across one funding round from two investors. In May 2026, Everads Therapy announced the publication of its first-in-human clinical data for its suprachoroidal injector in Ophthalmology Science.
Business overview
Everads Therapy is a life sciences company focused on developing retinal treatment delivery technologies. The company's core product is a delivery system designed to enhance the efficacy and safety of existing and new drug therapies for retinal and macular diseases. Operating within the RAD Biomed incubator in Tel Aviv, Israel, Everads Therapy serves the health tech and life sciences sectors, specifically focusing on medical devices, drug delivery, and biotechnology for eye diseases.
Strategic signal
In May 2026, Everads Therapy announced the publication of its first-in-human clinical data for its suprachoroidal injector in. This signifies a critical validation of the company's novel suprachoroidal delivery technology, demonstrating its potential to advance the treatment of retinal diseases and providing a strong signal of clinical progress and scientific recognition to investors.
Log in to access full profile ›Company Intelligence Q&A
- What is Everads Therapy's primary focus?
- Everads Therapy is an early-stage life sciences company developing retinal treatment delivery technologies to improve the efficacy and safety of injectable therapies for retinal and macular diseases.
- When was Everads Therapy founded and by whom?
- Everads Therapy was founded in January 2017 by Dr. Ifat Sher, Dr. Ygal Rotenstreich, and David Daily.
- What significant clinical milestone did Everads Therapy achieve in May 2026?
- In May 2026, Everads Therapy announced the publication of its first-in-human clinical data for its suprachoroidal injector in Ophthalmology Science, along with three presentations at ARVO 2026.
- Has Everads Therapy entered into any strategic partnerships for its technology?
- In August 2020, a global pharma company exercised rights for the exclusive use of Everads Therapy's drug delivery technology in specific retinal targets, following an option agreement entered in March 2020.
- What was the outcome of Everads Therapy's presentation at EURETINA in September 2024?
- In September 2024, Everads Therapy presented clinical data from its first-in-human trial of suprachoroidal delivery technology at EURETINA.